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Objective: Recently, the transcription factor AP-23 was shown to be a regulator of hypertrophy in cartilage 
and to be differentially expressed in osteoarthritis (OA). However, the only known target gene of AP-23 
up to date is integrin alpha10. To better characterize the function of AP-23 in cartilage we screened for 
additional target genes. 
Design: Promoter analysis, ChIP-assays and electrophoretic mobility shift assay were used to characterize 
the regulation of a new AP-23 target gene in detail. 
Results: In this study, we determined the chemokine CXCL1, already known to be important in osteo-
arthritis (OA), as a new target gene of AP-23. We could conﬁrm that CXCL1 is expressed in chondrocytes 
and signiﬁcantly over-expressed in OA-chondrocytes. Transient transfection of chondrocytes with an 
AP-23 expression construct led to a signiﬁcant increase of the CXCL1 mRNA level in these cells. We 
identiﬁed three potential AP-2 binding sites within the CXCL1 promoter and performed luciferase assays, 
indicating that an AP-2 binding motif (AP-2.2) ranging from position 135 to 144 bp relative to the 
translation start is responsive to AP-23. This result was further addressed by site-directed mutagenesis 
demonstrating that activation of the CXCL1 promoter by AP-23 is exclusively dependent on AP-2.2. 
Chromatin immunoprecipitation and electromobility shift assays conﬁrmed the direct binding of AP-23 
to the CXCL1 promoter in OA-chondrocytes at this site. 
Conclusion: These ﬁndings revealed CXCL1 as a novel target gene of AP-23 in chondrocytes and support 
the important role of AP-23 in cartilage. 
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. Introduction 
The family of AP-2 (activating enhancer-binding protein-2) 
transcription factors consists of ﬁve members: AP-2a, AP-2b, AP-2g, 
AP-2d and AP-23. They have a conserved basic-helix-span-helix 
DNA binding and dimerization domain at the C-terminus and a less 
conserved proline and glutamine-rich transactivation domain at 
the N-terminus1e4. For the regulation of target gene expression 
AP-2 proteins bind to the palindromic recognition sequence 
50-GCCN3/4GGC-30 or variations (e.g. 50-GCCN3/4GGG) within 
multiple gene promoters5. In vitro and in vivo analyses of AP-2 
knockout mice demonstrated the importance of AP-2 genes in 
numerous physiological processes during development, cell-cycle 
regulation and cell survival1,5. to: Anja-Katrin Bosserhoff, 
Franz-Josef-Strauss-Allee 11, 
5; Fax: 49-941-944-6602. 
burg.de (A.K. Bosserhoff). 
s Research Society International. PAP-23 is the last identiﬁed AP-2 transcription factor6,7. Expres-
sion of AP-23 was ﬁrst described in the olfactory system6, in skin 
and in in vitro cultured keratinocytes7. In previous studies we could 
show that AP-23 is also expressed in chondrocytes8. There it 
regulates the expression of integrin alpha10 which is the 
predominant type II collagen-binding integrin during cartilage 
development. Furthermore, we found that AP-23 plays a role in 
hypertrophic cartilage during cartilage differentiation and shows 
increased expression in osteoarthritic cartilage9. Additionally, we 
could identify Sox9 as a direct regulator of AP-23 expression9. 
The axial skeleton is formed by endochondral bone formation. 
This complex process starts with the migration of undifferentiated 
mesenchymal cells to regions which are deﬁned to differentiate 
into bones. These progenitor cells condense and stick together 
without increased proliferation10,11. They start to produce an 
extracellular matrix (ECM) containing type I collagen, hyaluronic 
acid, tenascin and ﬁbronectin12e14. Subsequent differentiation of 
the mesenchymal cells to chondrocytes causes a change of ECM 
composition. Chondrocytes express cartilage speciﬁc type II, type IX 
and type XI collagen, proteoglycans, aggrecan and cartilage derived ublished by Elsevier Ltd. All rights reserved. 
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I collagen stops. After further steps of differentiation chondrocytes 
become hypertrophic and express increased levels of type X 
collagen and reduce the expression of type II collagen15e17. Finally, 
osteoblasts inﬁltrate the cartilage and start to displace it with 
mineralized bone. Cartilage, which mainly consists of chondrocytes 
and ECM, serves as a protective layer for the joints. Degradation of 
the articular cartilage is a major problem in osteoarthritis (OA), 
a degenerative joint disorder, leading to destruction of the cartilage. 
The onset of the disease might be triggered by multiple factors such 
as mechanical overload, defects in the composition of the ECM or 
altered expression of transcription factors controlling the produc-
tion of matrix molecules18. 
In OA-chondrocytes several chemokines are up-regulated, 
including the CXC chemokine CXCL1 (C-X-C motif ligand 1) also 
known as growth-regulated protein a (GROa)19. CXCL1 belongs to 
the ELR-family of chemokines containing the characteristic amino 
acid sequence glutamic acideleucineearginine immediately before 
the ﬁrst cysteine of the CXC motif. Initially, CXCL1 was character-
ized by its growth stimulatory activity on malignant melanoma 
cells but several other functions have been described including its 
association with angiogenesis and inﬂammation20. During cartilage 
development CXCL1 induces chondrocyte hypertrophy and 
apoptosis21,22. 
In the present study we demonstrate that CXCL1 is a novel target 
gene of the transcription factor AP-23 in hypertrophic chondrocytes 
and OA-chondrocytes. 
Material and methods 
Cell culture 
Normal chondrocytes were isolated from healthy cartilage 
which was obtained following the standards of the Ethics 
Commission of the University of Regensburg or obtained from 
Cambrex (Iowa, USA) and cultured as suggested as described 
previously9. The proliferating cells are dedifferentiated in culture. 
To differentiate these cells they were stimulated with TGF-ß1 
(10 ng/ml) over 1 week. 
Human OA-chondrocytes were prepared from osteoarthritic 
cartilage slices which were obtained from patients who underwent 
total knee arthroplasty and have been giving informed consent 
following the standards of the Ethics Commission of the University 
of Regensburg. OA severity was evaluated as “end stage” for all 
individuals undergoing joint replacement surgery according to an 
arthroscopic score of grade III to IV23. Diagnosis of OA was per-
formed by orthopedic surgeons according to classiﬁcation criteria 
(clinical, radiographical and biochemical) of the American College 
of Rheumatology (ACR)24. Full thickness cartilage slices were 
aseptically dissected from healthy aspects of femoral condyles of 
patients aged 50e76 years. Speciﬁcally, prior to isolation of chon-
drocytes cartilage tissue was ﬁrst classiﬁed macroscopically as 
either “damaged” or “intact” according to a predeﬁned procedure 
comprising color, surface integrity and tactile impression tested 
with a standard scalpel. Accordingly, diseased areas showed 
a coloration that was rather yellow than white. They showed 
erosions and discrete protuberances that rendered it impossible to 
smoothly move the scalpel over the tissue surface. In unaffected 
regions there was a stronger resistance when cutting deeper into 
the tissue with the blade of the scalpel, which could not be done in 
the softened lesional areas25. For this study, we have prepared only 
cartilage slices classiﬁed as “damaged” and isolated chondrocytes 
from those cartilage regions. 
Human mesenchymal stem cells (HMSC) from CellSystems 
(St. Katharinen, Germany) were cultivated in mesenchymal stem cell growth medium (MSCGM) medium (CellSystems) under 
a humidiﬁed atmosphere of 5% CO2 at 37C26. To stimulate HMSC to 
either chondrogenic or osteoblastic differentiation cells were 
seeded in a 15 ml falcon and treated as previously described9. 
All primary cells used (normal chondrocytes, OA-chondrocytes 
and HMSC) were characterized for expression of Collagen type II 
(Coll2A1), Collagen type X (Coll10A1), matrix metalloproteinase-13 
(MMP-13) and melanoma inhibitory activity (MIA)/CD-RAP to 
conﬁrm cell-speciﬁc expression pattern25 (Suppl. Fig. 1). 
The chondrosarcoma cell line SW1353 was obtained from the 
American Type Culture Collection (ATCC, #HTB-94). Cells were 
maintained in Dulbecco’s modiﬁed eagle medium (DMEM) sup-
plemented with penicillin (400 U/ml), streptomycin (50 mg/ml), 
and 10% fetal bovine serum (Sigma, Deisenhofen, Germany) and 
split at a 1:5 ratio every 4 days. 
RNA isolation, reverse transcription and quantitative real-time 
polymerase chain reaction (PCR) 
For isolation of total cellular RNA from cultured cells or from 
tissue the RNeasy kit (QIAGEN, Hilden, Germany) was used. cDNAs 
were generated as described previously9. 
For a precise quantiﬁcation of cDNA expression the real-time 
PCR LightCycler system (Roche) was used as described previ-
ously27,28. Speciﬁc primer pairs were used for the qRTePCR analysis 
of AP-23 and CXCL1 expression: AP-23-for: 50-GAA ATA GGG ACT TAG 
CTC TTG G-30 and AP-23-rev: 50-CCA AGC CAG ATC CCC AAC TCT G-
30 , CXCL1_for: 50-CCC AAG AAC ATC CAA AGT GTG-30 and CXCL1_rev: 
50-GTT GGA TTT GTC ACT GTT CAG C-30 . To calculate expression 
ratios of the analyzed genes an internal control standard curve of b-
actin levels was used. 
Plasmid constructs 
The AP-23 expression construct (in pCMX-PL1) was a kind gift 
from M. Moser (Max-Planck-Institute of Biochemistry, Martinsried, 
Germany). 
To analyze the CXCL1 promoter for putative transcription factor-
binding sites, we screened approximately 1.5 kb of DNA of the 
upstream regulatory region, using the MATINSPECTOR (Genomatix 
Software GmbH, Munich, Germany). We determined three poten-
tial AP-2 binding sites (AP-2.1/2.2/2.3). 
To obtain the different promoter constructs used for luciferase 
assays human genomic regions of the CXCL1 promoter were 
ampliﬁed by PCR with speciﬁc primer pairs and cloned into lucif-
erase expression vectors. The following promoter constructs were 
generated: CXCL1prom128 (17 to 128), CXCL1prom299 (17 to 
299), CXCL1prom1448 (17 to 1448) in pGL3basic and CXCL1enh 
(1213 to 1448) in pGL3prom. 
Mutation of the potential AP-2 binding sites within the CXCL1 
promoter constructs was carried out with the QuikChange II Site-
Directed Mutagenesis Kit (Stratagene, USA) according to the 
manufacturer’s instructions. For mutation of the ﬁrst binding site 
(AP-2.1) the following primers were used: CXCL1prom_AP-
2.1mut_for: 50-GAG ACA TCT GCC CCT GCA GCA GAA GCC TCT G-30 
and CXCL1prom_AP-2.1mut_rev: 50-CAG AGG CTT CTG CTG CAG GGG 
CAG ATG TCT C-30. For mutation of the second binding site (AP-2.2) 
the following primers were used: CXCL1prom_AP-2.2mut_for: 
50-GGA ATT TCC CTG GTA CGG GGG CTC CGG G-30 and CXCL1pro-
m_AP-2.2mut_rev: 50-CCC GGA GCC CCC GTA CCA GGG AAA TTC C-30 . 
Transient transfection and luciferase assay 
Transient transfection of primary chondrocytes with the AP-23 
expression construct was performed using the Amaxa Nucleofector 
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Chondrocyte Nucleofector Kit according to the manufacturer’s 
instructions (program: U24). Cells were harvested 24 h later, and 
RNA was isolated. 
DNA transfection of the SW1353 cells was performed using 
Lipofectamine plus (Invitrogen, Carlsbad, CA, USA) as described 
previously9. 
Luciferase assays were performed as follows. Cells were cultured 
in six-well plates for 24 h and then treated with cationic lipid⁄ 
plasmid DNA suspension: 0.5 mg of luciferase reporter plasmid 
(CXCL1 promoter constructs or an empty pGL3basic vector as 
a control), 0.1 mg of the internal control plasmid pRL-TK and 
optionally 0.05 mg AP-23 expression plasmid or pCMX-PL1. 24 h 
after the transfection cells were harvested and the lysate was 
analyzed for luciferase activity with a luminometer using Promega 
dual-luciferase assay reagent (Promega Corporation, Madison, WI, 
USA). At least three independent transfection experiments were 
performed for each construct. 
Preparation of nuclear extracts 
Nuclear extracts from osteoarthritic chondrocytes were 
prepared by the method of Dignam et al.29. 
Electrophoretic mobility shift assay 
Electrophoretic mobility shift assay (EMSA) was performed as 
described previously9 and based on the binding of nuclear AP-23 to 
32P-labeled oligonucleotides containing an AP-23 binding site within 
the promoter of the analyzed AP-23 target gene CXCL1. The  following  
double-stranded oligomeric binding site for AP-23 was generated: 
CXCL1_oligo: 50-AATTTCCCTGGCCCGGGGGCT 
CCGGGCTT-30. This fragment corresponds to a promoter region 154 
to 126 upstream of the ATG of CXCL1 spanning the second AP-23 
binding site (AP-2.2). To demonstrate speciﬁcity of binding of AP-23 
a speciﬁc antiserum against AP-2330 and, as a control, an unrelated 
antibody was used. 
Chromatin immunoprecipitation assay (ChIP) 
The ChIP assay was performed using the ChIP-IT Express kit 
following the manufacturer’s instructions (Active Motif, Carlsbad, 
USA) and as previously described9. Chromatin isolation was per-
formed with chondrocytes from OA patients and samples were 
immunoprecipitated with a speciﬁc primary AP-23 antiserum30. An  
RNA polymerase II antibody was used as a positive control, and an 
IgG antibody as a negative control, following the protocol provided 
with the control kit (ChIP-IT control Kit-human; Active Motif). Four 
DNA templates from the ChIP experiments were used for analysis by 
PCR: input DNA (1:5), DNA isolated by RNA polymerase II ChIP (Pol 
II), by the negative control IgG ChIP (IgG), by the AP-23 ChIP (AP-23). 
A control reaction with no DNA template was also performed (H2O). 
Three sets of speciﬁc primer pairs were used for the PCR reaction: 
The glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the 
negative control primer pairs provided in the kit and a primer pair 
spanning the second AP-23 binding site (AP-2.2) within the 
promoter of CXCL1: CXCL1_prom2_for: 50-CCC AAG CGC TCC ACC CTG-
30 and CXCL1_prom2_rev: 50-CTC TCC GAG ATC CGC GAA C-30 (145 bp 
fragment). PCR fragments were analyzed on an 1.5% agarose gel. 
Statistical analysis 
Results are expressed as mean  SD (range) or percent. 
Comparison between groups was made using the Student’s paired 
t-test. A P value < 0.05 was considered statistically signiﬁcant. All calculations were performed using the GraphPad Prism software 
(GraphPad software Inc, San Diego, USA). Results 
To determine the role of AP-23 in cartilage differentiation, 
especially in hypertrophic chondrocytes, we searched for genes 
harbouring binding sites for AP-2 within their promoter sequences 
and showing an increased expression in hypertrophic and osteo-
arthritic chondrocytes. After an extensive literature study we used 
the MatInspector Software of Genomatix to perform promoter 
analysis for several candidate genes. This screening is based on 
known consensus binding sites for transcription factors. We 
analyzed several candidate genes and ﬁnally focused on the che-
mokine CXCL1. To conﬁrm the expression of CXCL1 in healthy and 
osteoarthritic chondrocytes we performed quantitative real-time 
PCR. As expected, CXCL1 is expressed in normal chondrocytes. In 
OA-chondrocytes the expression is signiﬁcantly increased up to 
43.3-fold (P ¼ 0.0084). To further analyze the inﬂuence of AP-23 on 
CXCL1 expression we transiently transfected chondrocytes with an 
AP-23 expression construct. Forced AP-23 expression leads to 
signiﬁcant 1.9-fold increase (P ¼ 0.049) of CXCL1 expression in 
these cells (data not shown). Those results indicate that CXCL1 
could be activated by the transcription factor AP-23. 
To further analyze whether AP-23 and CXCL1 are co-expressed 
during chondrocyte differentiation, we used an in vitro model 
system for HMSC differentiation into chondrocytes established in 
our lab. Marker genes for different stages of chondrogenesis like 
Coll2A1, Coll10A1, CD-RAP and aggrecan were analyzed to demon-
strate differentiation stages9. Using this model system the expres-
sion of AP-23 and CXCL1 mRNA was followed by quantitative 
RT-PCR over 40 days. Interestingly, the expression of both 
molecules increased coordinately during late chondrogenic 
differentiation starting at day 15 (data not shown). 
To get further insight into the regulatory mechanisms leading to 
up-regulation of CXCL1 in osteoarthritic chondrocytes we studied 
the promoter of CXCL1. We focused on 1500 bp upstream of the 
translation start site. Analysis of this region with the MatInspector 
software offered three potential AP-2 binding motifs located at base 
pair 1390 to 1398 (AP-2.1), 135 to 144 (AP-2.2) and 59 to 
67 (AP-2.3) relative to the translation start (ATG) (Fig. 1). 
To test whether AP-23 can activate the CXCL1 promoter we 
performed luciferase assays with different promoter constructs. 
First a CXCL1 promoter construct ranging from position 17 to 
1448 bp including all three predicted AP-2 binding sites was 
cloned into a reporter gene plasmid containing a promoter-less 
luciferase gene (CXCL1prom1448). SW1353 cells were transiently 
transfected with this plasmid and luciferase activity was measured. 
Compared to the control (pGL3basic) CXCL1prom1448 shows 
strongly increased promoter activity (Fig. 2). Co-transfection of an 
AP-23 expression plasmid results in a 2.5-fold increase of luciferase 
activity of CXCL1prom1448 while the control plasmid is not acti-
vated. This assay conﬁrms that the 1448 bp region of the CXCL1 
promoter is indeed responsive to AP-23. 
To test whether one, two or all three of the identiﬁed AP-2 
binding sites are involved in this activation process we designed the 
following promoter constructs: CXCL1prom128 (17 to 128) 
which contains only AP-2.3 and CXCL1prom299 (17 to 299) 
including AP-2.2 and AP-2.3. CXCL1prom128 exhibits far less 
promoter activity compared to the 1448 construct, whereas 
CXCL1prom299 is even slightly more active (Fig. 2). Forced AP-23 
expression does not increase the activity of the 128 construct 
implying that AP-2.3 is no binding site of AP-23. On the other hand 
co-transfection of AP-23 does increase the activity of the 299 
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Fig. 1. Schematical overview of the CXCL1 promoter. 
Putative AP-2 binding sites are marked within the sequence. 
Fig. 2. Regulation of the CXCL1 promoter by AP-23.
 
Promoter constructs ranging from 17 up to 128, 299 and 1448, respectively, were sub-cloned into pGL3basic, and promoter activity was analyzed in SW1353 cells. Addi-
tionally, an expression construct for AP-23 was co-transfected into SW1353 cells and promoter activity was measured. CXCL1prom1448 is set as one. Data are given as means. 95%
 
conﬁdence intervals were used to represent uncertainty of estimates.
 
All experiments were repeated at least three times.
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Fig. 3. Mutagenesis of AP-2 binding sites in the CXCL1 promoter.
 
CXCL1 promoter constructs with or without mutated AP-2 binding sites were sub-cloned into pGL3basic, and promoter activity was analyzed in SW1353 cells. Additionally, an
 
expression construct for AP-23 was co-transfected into SW1353 cells, together with the CXCL1 promoter constructs, and promoter activity was measured. A: Analysis of the 299
 
promoter construct containing a mutated AP-2.2 site. CXCL1prom299 is set as one B: Analysis of the 1448 promoter construct containing a mutated AP-2.1 and/or AP-2.2 site.
 
CXCL1prom1448 is set as one. Data are given as means. 95% conﬁdence intervals were used to represent uncertainty of estimates. All experiments were repeated at least three times.
 construct, suggesting that AP-2.2 might indeed be an AP-23 binding 
site (Fig. 2). 
To address this questionwe mutated AP-2.2 in CXCL1prom299, and 
AP-2.1 and/or AP-2.2 in CXCL1prom1448 and measured luciferase 
activity. The mutation of AP-2.2 in the 299 construct (CXCL1pro-
m299_AP-2.2*) leads to decreased promoter activity compared to 
the wild-type 299 construct [Fig. 3(A)]. Even more interesting, co-
transfection of an expression plasmid for AP-23 results in no increase 
of promoter activity when AP.2.2 is mutated whereas the wild-type 
299 construct is signiﬁcantly induced by AP-23. This demonstrates  
that AP-23 activates the CXCL1 promoter at AP-2.2. 
Mutation of AP-2.1 ranging from base pair 1390 to 1398 in 
the 1448 construct (CXCL1prom1448_AP-2.1*) does not lower the 
luciferase activity of this construct compared to the wild-type 
1448 construct. Co-transfection of AP-23 still signiﬁcantly Fig. 4. Regulation of the distal CXCL1 promoter region by AP-23.
 
A CXCL1 promoter construct (CXCL1enh) from position 1213 to 1448 bp containing the po
was analyzed in SW1353 cells. Additionally, an expression construct for AP-23 was co-trans
Data are given as means. 95% conﬁdence intervals were used to represent uncertainty of eincreases promoter activity by about 2.7-fold [Fig. 3(B)]. On the 
other hand, individual mutation of AP-2.2 (CXCL1prom1448_AP-
2.2*) as well as in conjunction with AP-2.1 (CXCL1prom1448_AP-
2.1*/2.2*) strongly reduces promoter activity and leads to 
a promoter sequence that cannot be induced by AP-23 anymore 
[Fig. 3(B)]. 
To conﬁrm that AP-2.1 is not responsive to AP-23 we analyzed 
the site independently of AP-2.2. Therefore, we cloned a 235 bp 
fragment ranging from base pair 1213 to 1448 into a reporter 
gene plasmid containing a luciferase gene with a SV40 promoter 
(CXCL1enh) and carried out luciferase assays once more. As can be 
seen in Fig. 4 the control vector and CXCL1enh, respectively, are not 
induced by AP-23. 
To demonstrate the direct binding of AP-23 to the AP-2.2 site in 
the CXCL1 promoter we performed electromobility shift assays with tential AP-2 binding site AP-2.1 was sub-cloned into pGL3prom, and promoter activity
 
fected into SW1353 cells and promoter activity was measured. CXCL1enh is set as one.
 
stimates. All experiments were repeated at least three times.
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Fig. 5. Direct binding of AP-23 to the CXCL1 promoter. A: Electromobility shift assay to demonstrate the binding of AP-23 to the CXCL1 promoter. AP-23 binding was shown using 
labeled oligonucleotides spanning the second AP-2 binding site AP-2.2 (lane 2) incubated with nuclear extract of osteoarthritic chondrocytes. For competition experiments 
unlabeled oligonucleotides (lane 3) were used in excess. A speciﬁc AP-23 antibody was used to conﬁrm the speciﬁcity of AP-23 binding (lane 4) whereas no binding to an unrelated 
antibody was observed (lane 5). B: A ChIP assay demonstrates the direct binding of AP-23 to the CXCL1 promoter. DNA samples of ChIP reactions (Pol II, IgG, and AP-23) and input 
DNA were used in PCRs with different primer pairs (GAPDH, negative control primers, AP-23). All PCR fragments could be detected in the input DNA sample. A PCR product was 
generated using the AP-23 ChIP DNA (CXCL1, lane 3). a labeled oligonucleotide spanning the second potential AP-2 
binding site (AP-2.2). Figure 5(A) depicts that incubation of oligo-
nucleotide AP-2.2 with nuclear extract of OA-chondrocytes leads to 
the generation of a complex (lane 2). Incubation with an excess of 
unlabeled oligonucleotides (comp) could completely displace this 
complex (lane 3). The speciﬁcity of AP-23 binding was conﬁrmed by 
incubation with a speciﬁc AP-23 antibody (lane 4) leading to the 
generation of a supershifted complex whereas using an unrelated 
antibody no supershift was observed. These data demonstrate that 
the transcription factor AP-23 binds to the AP-2 binding site AP-2.2 
within the CXCL1 promoter. 
Additionally, the direct binding of AP-23 to the CXCL1 promoter 
was supported by chromatin immunoprecipitation assays with 
chromatin isolated from osteoarthritic chondrocytes. Again, 
binding of AP-23 to the AP-2.2 binding site of the CXCL1 promoter 
could be revealed [Fig. 5(B)].  Discussion 
Recently, we could show that the transcription factor AP-23 is 
a positive regulator of integrin alpha10 expression in chondrocytes8. 
The aim of this study was to specify the processes during cartilage 
development induced by AP-23. Therefore, we looked for other AP-23 
target genes in chondrocytes besides integrin alpha10. Using  this
strategy, we hoped to learn more about the functional relevance of AP-
23 for chondrogenesis and the development of the cartilage disease OA. 
The promoter of the chemokine CXCL1 contains three potential 
AP-2 consensus binding sites (AP-2.1/2.2/2.3). We revealed that 
only the AP-2 binding site at position 135 to 144 bp (AP-2.2) is 
important. Our results, therefore, demonstrate that the predicted 
binding site AP-2.2 is necessary and sufﬁcient for the activation of 
the CXCL1 promoter by AP-23. 
Performing electromobility shift assays and ChIP assays the 
direct binding of AP-23 to the CXCL1 promoter at AP-2.2 could be 
conﬁrmed. Enhanced expression of AP-23 in chondrocytes leads to 
an increased expression of CXCL1 in these cells. The results shown 
here point out that the transcription factor AP-23 is a positive 
regulator of CXCL1 in chondrocytes. CXCL1 is already known to be expressed in chondrocytes and 
also the functional role of CXCL1 during chondrocyte differentiation 
is well analyzed21. Together with IL-8 this chemokine induces 
hypertrophic differentiation of articular chondrocytes and calciﬁ-
cation through p38 MAPK activation and transglutaminase 221. This 
leads to an induction of apoptosis which is dependent on additional 
signals from the ECM and matrix degrading activity31,22. Further-
more, in OA, chondrocyte hypertrophy and apoptosis can cause 
dysregulation of matrix repair by alteration in collagen subtype and 
MMP expression, and in cell viability32,33. 
The expression of AP-23 is induced by the transcription factor 
Sox9 in the beginning of hypertrophic cartilage development9. This 
study now demonstrates that AP-23 activates CXCL1 expression. 
This induction of CXCL1 expression via AP-23 leads to differentia-
tion and calciﬁcation of articular chondrocytes and in case of OA 
can force matrix degradation. Further studies are necessary to 
conﬁrm the functional role of AP-23 as a regulator of more target 
genes important for late chondrocyte differentiation. In summary, 
our data clearly show that the transcription factor AP-23 activates 
CXCL1 expression in chondrocytes and osteoarthritic chondrocytes 
through direct binding to the CXCL1 promoter. Author contributions 
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